Join Growin Stock Community!

新穎生醫6810.TW Overview

TW StockBiotech. & Medical
(No presentation for 6810)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

新穎生醫（6810）Overall Performance

新穎生醫（6810）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

新穎生醫（6810） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

新穎生醫（6810）Key Information

新穎生醫（6810）Profile

Bio Preventive Medicine Corp, a clinical-staged biotech company, focusing on early detection and prevention of diseases. The company offers solutions in prevention, screening, and monitoring chronic diseases and cancers management. It provides DNlite test, a series of patented and clinically validated non-invasive urine test for diabetic kidney disease management, such as DNlite-IVD103 and DNlite-DN_Score. The company was founded in 2014 and is headquartered in Zhubei, Taiwan.

新穎生醫（6810）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.40
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
70.90
PB Ratio
2.55
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
96.60%
Net Margin
-1304.90%
Revenue Growth (YoY)
322.01%
Profit Growth (YoY)
356.82%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.40
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
70.90
PB Ratio
2.55
Price-to-FCF
-
Gross Margin
96.60%
Net Margin
-1304.90%
Revenue Growth (YoY)
322.01%
Profit Growth (YoY)
356.82%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
default symbol

6810

新穎生醫

18.45D

-1.90%

(-0.02)

  • When is 6810's latest earnings report released?

    The most recent financial report for 新穎生醫 (6810) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6810's short-term business performance and financial health. For the latest updates on 6810's earnings releases, visit this page regularly.

  • How much cash does 6810 have?

    At the end of the period, 新穎生醫 (6810) held Total Cash and Cash Equivalents of 300.13M, accounting for 0.63 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6810 go with three margins increasing?

    In the latest report, 新穎生醫 (6810) did not achieve the “three margins increasing” benchmark, with a gross margin of 91.35%%, operating margin of -4,735.29%%, and net margin of -4,720%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6810's profit trajectory and future growth potential.